For UK financial adviser use only. This information has not been approved for use with customers. If you are a customer please go to


We use cookies to give you the best possible online experience. If you continue, we'll assume you are happy for your web browser to receive all cookies from our website. See our cookie policy for more information on cookies and how to manage them.

Our view on the Competition Commission's findings

Published: 30 Aug 2013

Following the publication of the provisional findings from the Competition Commission’s inquiry into the private healthcare market, at Aviva, we are greatly encouraged by the remedies proposed. The investigation by the Commission has identified problems with competition in the private healthcare market giving rise to customer detriment to the value of between £173 million and £193 million per year, and made strong recommendations to tackle this.  

We believe that the proposals set out in the notice of possible remedies will improve the healthcare market for the people it serves. This will be achieved through greater competition between providers and greater transparency over the cost and quality of consultant and hospital services.

Private Medical Insurance provides an incredibly valuable benefit for both customers and employers and we want to make it more affordable without compromising quality and service.  We believe the recommendations from the Competition Commission will help to achieve this and we look forward to continuing to work with them.

Of course, as I talked about back in April we will also continue to focus on driving better value for all of our customers through expense and claims management. We have already launched new propositions this year including BacktoBetter and GuideWell demonstrating our commitment to delivering improved outcomes for customers and managing costs in a more sustainable way.

If you would like further information about the Competition Commission findings, please click here and you can also read our short report on what we’ve done to support the investigation.

Also, have a look at the views of Al Wighton, our Market Development Director on the provisional findings.

Mark Noble 

Managing Director - Health and Group Risk


Share |

Can we help you?

Think of us as part of your team.

Find the right details on our Contact Us page